Ischemic Heart Disease (IHD) Drugs Market Report 2026

Ischemic Heart Disease (IHD) Drugs Market Overview

• Ischemic Heart Disease (IHD) Drugs market size has reached to $6.65 billion in 2025 • Expected to grow to $7.99 billion in 2030 at a compound annual growth rate (CAGR) of 3.7% • Growth Driver: Rising Heart Failure Cases Drive Surge In Ischemic Heart Disease (IHD) Drugs Market Growth • Market Trend: Regulatory Momentum And Indication Expansions Strengthening Therapeutic Advancements In Ischemic Heart Disease • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Ischemic Heart Disease (IHD) Drugs Market?

Ischemic heart disease (IHD) drugs are medications used to manage and treat a condition characterized by reduced blood flow to the heart muscle, often due to coronary artery narrowing. These drugs aim to alleviate symptoms, reduce the risk of complications such as heart attacks, and improve overall cardiac function. The main types of drug classes included in ischemic heart disease (IHD) drugs are anti-dyslipidemic drugs, calcium channel blockers, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), vasodilators, and antithrombotic agents. Anti-dyslipidemic drugs are pharmacological agents that target and lower abnormal levels of lipids (such as cholesterol and triglycerides) in the bloodstream to reduce the risk of cardiovascular disease. These are used to treat various classes of disease, including angina pectoris and myocardial infarction, and are used by several end users, such as hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Ischemic Heart Disease (IHD) Drugs Market Growth Forecast?

The ischemic heart disease (ihd) drugs market size is expected to see steady growth in the next few years. It will grow to $7.99 billion in 2030 at a compound annual growth rate (CAGR) of 3.7%. The growth in the forecast period can be attributed to advancements in precision medicine, integration of digital health solutions, growth in combination therapy adoption, development of novel drug delivery systems, expansion of telehealth and remote monitoring. Major trends in the forecast period include personalized cardiac therapy, combination drug formulations, telemedicine-enabled cardiac care, cardiovascular risk prediction & monitoring, minimally invasive drug delivery.

Global Ischemic Heart Disease (IHD) Drugs Market Segmentation

1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents 2) By Disease Class: Angina Pectoris, Myocardial Infarction 3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy Subsegments: 1) By Anti-Dyslipidemic Drugs: Statins, Fibrates, Niacin, Cholesterol Absorption Inhibitors 2) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines 3) By Beta-Blockers: Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, Vasodilating Beta-Blockers 4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril 5) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan 6) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate, Hydralazine 7) By Antithrombotic Agents: Antiplatelet Drugs, Anticoagulants

What Is The Driver Of The Ischemic Heart Disease (IHD) Drugs Market?

The increasing incidence of heart failure is expected to propel the growth of the ischemic heart disease (IHD) drug market going forward. Heart failure is a chronic condition in which the heart muscle is unable to pump enough blood to meet the body's needs for blood and oxygen. This can lead to fatigue, shortness of breath, and difficulty performing everyday activities. Ischemic heart disease (IHD) drugs play an important role in the treatment of heart failure. To reduce the risk factors and symptoms of ischemic heart disease, these medications can help avoid heart failure. Ischemic Heart Disease (IHD) drugs inhibit the pacemaker activity of the heart and are beneficial in heart failure patients with reduced ejection fractions and high resting heart rates after a tolerated beta-blocker. For instance, in September 2023, according to the Heart Failure Society of America, a US-based organization, 6.7 million Americans over 20 years of age have heart failure (HF), and the prevalence is expected to rise to 8.5 million Americans by 2030. Therefore, the increasing incidence of heart failure is driving the growth of the ischemic heart disease (IHD) drug industry.

Key Players In The Global Ischemic Heart Disease (IHD) Drugs Market

Major companies operating in the ischemic heart disease (ihd) drugs market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., Novitium Pharma LLC

Global Ischemic Heart Disease (IHD) Drugs Market Trends and Insights

Major companies operating in the ischemic heart disease (IHD) drugs market are focusing on advancing regulatory approvals and expanding drug indications to strengthen therapeutic options and capture greater market share. For instance, in June 2023, Bristol Myers Squibb, a US-based biopharmaceutical company, announced that the European Commission approved Camzyos (mavacamten), the first allosteric, selective cardiac myosin inhibitor for treating symptomatic NYHA class II–III obstructive hypertrophic cardiomyopathy (HCM). In the same year in the U.S., the FDA approved a supplemental new drug application based on Phase 3 VALOR HCM data showing a significant reduction in eligibility for septal reduction therapy among treated patients. Therefore, increasing regulatory momentum and label expansions for myosin inhibitors are driving growth in the IHD drug market.

What Are Latest Mergers And Acquisitions In The Ischemic Heart Disease (IHD) Drugs Market?

In March 2024, Novo Nordisk, a Denmark-based pharmaceutical company, acquired cardior pharmaceuticals for an undisclosed amount. The acquisition is a significant step in Novo Nordisk's strategy to establish and expand its portfolio in cardiovascular disease, which is a leading cause of mortality worldwide. Cardior pharmaceuticals is a Germany-based pharmaceutical company manufacturing cardiovascular drugs for IHD.

Regional Insights

North America was the largest region in the ischemic heart disease (IHD) drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Ischemic Heart Disease (IHD) Drugs Market?

The ischemic heart disease (IHD) drugs market consists of sales of antiarrhythmic drugs, anticoagulants, anti-anginal medications, nitroglycerin and nitrates, statins, and antiplatelet agents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Ischemic Heart Disease (IHD) Drugs Market Report 2026?

The ischemic heart disease (ihd) drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the ischemic heart disease (ihd) drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.